Viral polymerase inhibitors
AssigneeBoehringer Ingelheim International GmbH
InventorsYoula S. Tsantrizos, Catherine Chabot, Pierre Beaulieu, Christian Brochu, Timothy A. Stammers, Bounkham Thavonekham, Jean Rancourt
Life of this patent
Estimating the term…
Abstract
An enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein, or a salt or ester thereof, as an inhibitor of HCV NS5B polymerase.
Claims23
A compound selected from:
- or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof.
A compound selected from
- or the pharmaceutically acceptable salts thereof.
A compound having the structure
- or the pharmaceutically acceptable salts thereof.
A compound having the structure
- or the pharmaceutically acceptable salts thereof.
A compound having the structure
- or the pharmaceutically acceptable salts thereof.
A compound having the structure
- or the pharmaceutically acceptable salts thereof.
A compound having the structure
- or the pharmaceutically acceptable salts thereof.
A compound having the structure
- or the pharmaceutically acceptable salts thereof.
A compound having the structure
- or the pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.